Class Actions · Mass Torts · Securities FraudCall (918) 238-6445

Active Cases

Pending securities class actions with reported lead plaintiff deadlines, and mass tort litigation in which new claims are being filed.

Case Evaluation

Cases filed by the firm

Matters in which Schwartz & Associates, PC is counsel of record. Descriptions summarize allegations in court filings; allegations are not findings, and prior results do not guarantee a similar outcome.

Firm case

LaChance v. TruGolf Holdings, Inc., et al.

NASDAQ: TRUG · D. Utah · 1:26-cv-00119-JNP-CMR · filed July 24, 2026

The complaint alleges that defendants misrepresented or failed to disclose that holders of TruGolf's Series A Convertible Preferred Stock were continuously converting into Class A shares at floating and ratcheting conversion prices, causing substantial ongoing dilution, and that TruGolf's April 15, 2026 Form 10-K overstated its outstanding Class A shares by 480,504 shares, or approximately 52%. The complaint alleges that the financing and related misstatements contributed to a decline of more than 98% in the split-adjusted price of TruGolf's Class A common stock.

Class period
September 10, 2025 to May 20, 2026
Lead plaintiff deadline (passed)
September 28, 2026
Claims
Securities Act Sections 11 and 15; Exchange Act Sections 10(b), 14(a) and 20(a); related shareholder derivative claims
The firm's role
Schwartz & Associates, PC is counsel of record for the plaintiff in this action, the first-filed securities class action concerning TruGolf.

Public records

Pending cases

Pending securities class actions with reported lead plaintiff deadlines, and mass tort litigation still open to new filings. Compiled as of November 21, 2026.

Unless marked Firm case, the firm is not counsel in these cases. Descriptions of filed cases summarize allegations in court complaints; allegations are not findings. Verdicts and settlements in other people's cases do not predict the outcome or value of any other claim. Deadlines are compiled from public notices and dockets and are not verified against the statutory notice; confirm any date on the court docket before relying on it.

What a lead plaintiff deadline means. It applies only to an investor who wants to ask the court to appoint them lead plaintiff, and it runs 60 days from publication of the statutory notice under 15 U.S.C. §§ 77z-1(a)(3) and 78u-4(a)(3). You do not need to do anything by that date to remain a member of any class that may be certified. Three things matter later: to receive money from a settlement you will ordinarily need to submit a claim form by a deadline; if you do not exclude yourself by the deadline in the court's notice, you are bound by the result; and statutory time limits may run regardless of the class action, so anyone considering an individual case should get advice promptly.

Open investigations

An investigation is not a filed case. A description of an investigation does not mean that a lawsuit has been filed or that any wrongdoing has been established.

Company and conductStatusOpenedMore
Redwire Corporation NYSE: RDW
The firm is investigating whether Redwire Corporation and its officers accurately disclosed the shareholder dilution risk, capital needs, and cash-burn trajectory behind a series of large equity offerings, and whether investors received a complete and accurate picture of the company's financial condition.
Investigation, no case filed June 29, 2026 Learn more
SoFi Technologies, Inc. NASDAQ: SOFI
The firm is investigating whether SoFi Technologies, Inc. accurately reported key financial metrics to investors, including how it classified certain borrowings, whether adjusted EBITDA was overstated, and whether personal-loan charge-off rates were fully disclosed.
Investigation, no case filed June 27, 2026 Learn more
Core Scientific, Inc. NASDAQ: CORZ
The firm is investigating whether Core Scientific, Inc. and its officers adequately disclosed the accounting errors and internal control weaknesses that led the company to restate financial statements, and whether investors were misled while those issues remained undisclosed.
Investigation, no case filed June 16, 2026 Learn more
Super Micro Computer, Inc. NASDAQ: SMCI
The firm is investigating whether Super Micro Computer, Inc. adequately disclosed material weaknesses in its internal control over financial reporting, and whether investors received accurate information about the reliability of the company's financial reporting during a period of rapid, AI-driven revenue growth.
Investigation, no case filed June 16, 2026 Learn more
DoorDash, Inc. NYSE: DASH
The firm is investigating whether DoorDash, Inc. clearly and accurately discloses the fees consumers pay, whether menu prices on the platform differ from in-store prices without adequate notice, and whether DashPass subscription savings claims and automatic-renewal terms are presented fairly.
Investigation, no case filed February 11, 2026 Learn more

Securities class actions

Company and allegationsClass periodReported lead plaintiff deadlineCourt and docketAsk
Honeywell Aerospace, Inc. NASDAQ: HONA
The complaint alleges that defendants failed to disclose that a small percentage of suppliers had a disproportionate impact on sales and were supply constrained, and that the company was under investigation for potential False Claims Act violations tied to cybersecurity requirements in government contracts. The stock allegedly fell $47.17, or 23.16%, after the August 2026 earnings release with reduced growth guidance, and a further $3.87, or 2.45%, on September 1, 2026 after a Justice Department settlement announcement.
June 29, 2026 to September 1, 2026 November 23, 2026
D. Ariz.
2:26-cv-06779
Ask about this
Tigo Energy, Inc. NASDAQ: TYGO
The complaint alleges that Tigo's revenue projections depended on the launch of its EG4 Electronics partnership, which would not provide material revenue until the fourth quarter of 2026 at the earliest, so the projections allegedly lacked a reasonable basis. On August 4, 2026, Tigo cut full-year 2026 revenue guidance from $130 to $135 million to $100 to $110 million, citing the partner's delayed launch, and the stock allegedly fell from $2.04 to $1.29 on August 5.
February 24, 2026 to August 4, 2026 November 23, 2026
N.D. Cal.
5:26-cv-10888
Ask about this
Fluence Energy, Inc. NASDAQ: FLNC
The complaint alleges that defendants failed to disclose that Fluence's ability to deliver backlog and recognize fiscal 2026 revenue depended on new contract manufacturing facilities that were not complete or able to produce at the volumes guidance assumed, and that corrective measures were not fixing persistent production problems. The stock allegedly fell 34.63% on February 5, 2026, 7.17% on August 6, 2026, and $1.39, or 15.36%, to $7.66 on September 17, 2026.
November 24, 2025 to September 16, 2026 November 27, 2026 or November 30, 2026
Added by the firm's daily review on September 29, 2026 from the court docket or the statutory notice. Confirm the deadline against the docket before relying on it. The notices differ on the deadline: one states November 30, 2026; another states 60 days from September 28, 2026 (November 27). Both dates are shown.
E.D. Va.
1:26-cv-08475
Ask about this
Qfin Holdings, Inc. NASDAQ: QFIN
The complaint alleges that Qfin Holdings and certain officers made materially false and misleading statements regarding the resiliency and stability of the company's business and financial results despite regulatory changes affecting China's credit technology sector, and downplayed the severity of the negative impact of regulatory headwinds on the company's business. The complaint alleges that on August 25, 2026, Qfin announced second quarter and interim 2026 unaudited financial results showing net income fell sharply year over year, including an unexpected tax expense, which caused the stock price to decline and damaged investors who purchased during the Class Period.
March 18, 2026 to August 25, 2026 November 27, 2026
E.D.N.Y.
26-cv-06024
Ask about this
Alphabet Inc. NASDAQ: GOOGL
The complaint alleges that Alphabet and certain executives failed to disclose that its Gemini 3.5 Pro AI model was delivering disappointing training results and that the model's launch would be significantly delayed, rendering positive statements about the company's AI business materially misleading. The complaint alleges that on July 16, 2026, Bloomberg reported Google was months behind schedule on delivering Gemini 3.5 Pro due to disappointing training results, after which Alphabet's stock price declined sharply.
May 19, 2026 to July 16, 2026 November 30, 2026
N.D. Cal.
3:26-cv-11290
Ask about this
Anavex Life Sciences Corp. NASDAQ: AVXL
The complaint alleges that Anavex Life Sciences lacked adequate internal controls and understated potential regulatory challenges arising from misconduct by former CEO Christopher Missling. The complaint alleges that on May 6, 2026 Anavex disclosed Missling's termination for conduct inconsistent with company policy, and later, on August 28, 2026, filed amended annual and quarterly reports disclosing material weaknesses in internal control over financial reporting, with the company's stock falling $0.18 per share, or 5.55%, on May 12, 2026 as related news emerged.
November 26, 2025 to August 28, 2026 November 30, 2026
S.D.N.Y.
1:26-cv-08567
Ask about this
Endava plc NYSE: DAVA
The complaint alleges that Endava and certain officers made materially false and misleading statements and failed to disclose that the accounting treatment for certain customer and supplier agreements required additional review, that the company would delay release of its fourth quarter and full year 2026 financial results, and that there was reason to doubt the effectiveness of its internal controls. The complaint alleges the truth emerged after the market closed on September 21, 2026, when Endava announced that its CFO had been placed on administrative leave pending an internal investigation triggered by outside auditors' concerns about the accounting treatment of certain customer and supplier agreements, and that its ADS price fell $0.68 per share, or 24.37%, to close at $2.11 on September 22, 2026.
September 4, 2025 to September 21, 2026 November 30, 2026
S.D.N.Y.
1:26-cv-08556
Ask about this
Coastal Financial Corporation NASDAQ: CCB
The complaint alleges that Coastal Financial Corporation and certain officers made materially false and misleading statements about the growth and credit quality of the company's CCBX banking-as-a-service business, the adequacy of its risk management and credit reporting practices, and the credit protections afforded by its CCBX partner indemnification agreements. The complaint alleges that the truth was revealed on July 30, 2026 when Coastal announced second quarter 2026 results showing a surprise GAAP net loss of $42.1 million driven by a $68.8 million credit expense tied to a single CCBX partner relationship, and that on this news the company's stock price fell approximately 43.5%, erasing roughly $470 million in market capitalization.
October 28, 2024 to July 29, 2026 December 1, 2026
W.D. Wash.
2:26-cv-03746
Ask about this
Duolingo, Inc. NASDAQ: DUOL
The complaint alleges that Duolingo and certain executives made materially false or misleading statements about daily active user growth, concealing that the company was deliberately adding user friction through increased ad volume and subscription upsells and relying on rapidly produced, lower-quality AI content that was harming the user experience. The complaint alleges the truth emerged through a series of disclosures, including an announcement reversing the monetization push in November 2025 and the February 26, 2026 fourth-quarter results confirming slowed DAU growth and weak 2026 guidance. The complaint alleges that Duolingo shares fell sharply following these disclosures, including a decline of roughly 14% after the February 26, 2026 announcement.
May 2, 2025 to February 26, 2026 December 7, 2026
W.D. Pa.
2:26-cv-02197
Ask about this
Netcapital Inc. NASDAQ: NCPL
The complaint alleges that Netcapital and certain officers improperly recognized revenue from sham, backdated and in some instances forged consulting agreements with entities controlled by a company insider, and engaged in undisclosed related-party transactions that inflated reported revenue. The complaint alleges that the fraud was revealed when the SEC filed an enforcement complaint against Netcapital and individual defendants on August 10, 2026 alleging the same scheme, after which the company's auditor withdrew.
December 15, 2021 to September 3, 2026 December 7, 2026
D. Mass.
1:26-cv-14584
Ask about this
The Chemours Company NYSE: CC
The complaint alleges that Chemours and certain executives made materially false and misleading statements about aftermarket demand for its Opteon refrigerant products and the reliability of its fiscal 2026 financial guidance. The complaint alleges that Chemours overstated aftermarket demand for Opteon products sold through its Thermal & Specialized Solutions segment despite an oversupplied channel heading into 2026. The complaint alleges that when the guidance cut and channel oversupply were disclosed on August 4-5, 2026, Chemours stock fell $3.34 per share, or about 18.6%, to close at $14.59 per share.
February 20, 2026 to August 4, 2026 December 7, 2026
D. Del.
1:26-cv-01299
Ask about this
The Ensign Group, Inc. NASDAQ: ENSG
The complaint alleges that Ensign and certain executives made materially false and misleading statements about the company's skilled nursing facility operations, including that Ensign's business model and profitability depended on systematic understaffing and neglect of residents, that self-reporting compliance measures concealed these practices, and that the company engaged in an improper scheme of renting administrator licenses to create a false appearance of regulatory compliance at its facilities. The complaint alleges the truth emerged through a series of short-seller reports beginning June 8, 2026 (Hunterbrook Media) and continuing through a June 18, 2026 follow-up report, which were followed by declines in Ensign's stock price. Investors who purchased Ensign securities during the class period allege they suffered losses as the stock fell from prior highs following these disclosures.
February 10, 2022 to June 18, 2026 December 7, 2026
C.D. Cal.
8:26-cv-02963
Ask about this
Webull Corporation NASDAQ: BULL
The complaint alleges that Webull overstated its independence from mainland China, including claims that its primary operations were U.S.-based and that U.S. customer data was protected from non-U.S. access, while its software development, data pipelines, and core engineering allegedly depended on PRC-based personnel and infrastructure. The complaint alleges that on October 7, 2026, CNBC reported findings from the House Select Committee on China detailing extensive ties between Webull and China, after which Webull shares fell approximately 19% to close at $5.89.
April 26, 2025 to October 6, 2026 December 7, 2026
M.D. Fla.
8:26-cv-03052
Ask about this
Compass, Inc. NYSE: COMP
The complaint alleges that the offering materials issued in connection with Compass's January 9, 2026 stock-for-stock merger with Anywhere Real Estate misrepresented and omitted material information concerning defendants' attestations to use reasonable best efforts to obtain required regulatory authorizations and consents, as well as their compliance with applicable laws and the absence of governmental investigations. The complaint further alleges, according to related reporting, that Compass sought to use an attorney connected to the prior administration as an improper back-channel to expedite Department of Justice review of the merger. The suit is brought on behalf of former Anywhere shareholders who received newly issued Compass common stock in the merger exchange.
See case description December 8, 2026
S.D.N.Y.
1:26-cv-08885
Ask about this
Millrose Properties, Inc. NYSE: MRP
The complaint alleges that Millrose and certain executives made false and misleading statements that the company's business was limited to land purchases, horizontal development, and homesite option purchase arrangements for Lennar and other homebuilders, and would not involve entering into lease agreements. The complaint alleges that an October 2, 2026 report revealed Millrose had purchased an estimated $200 million of finished homes from its former parent Lennar and was renting them out, reportedly at a loss. The complaint alleges that on this news Millrose shares fell roughly 8.5%, or about $2.10 per share.
February 7, 2025 to October 2, 2026 December 8, 2026
S.D. Fla.
9:26-cv-81386
Ask about this
Gildan Activewear Inc. NYSE: GIL
The complaint alleges that Gildan and certain executives made false and/or misleading statements and failed to disclose that the company lacked adequate internal controls and used channel stuffing to create an appearance of revenue growth. The complaint alleges the truth began to emerge on June 16, 2026 when a short seller report accused Gildan of pushing excess product into its distribution channel beyond underlying demand, after which Gildan shares fell approximately 18.7 percent in a single trading session. The complaint alleges that as a result, defendants' prior statements about Gildan's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis.
February 19, 2025 to June 15, 2026 December 14, 2026
N.D.N.Y.
1:26-cv-02126
Ask about this
Triller Group Inc. (formerly AGBA Group Holding Limited) NASDAQ: ILLR
The complaint alleges that Triller and certain executives made false and misleading statements and failed to disclose that the company's control over and consolidation of the Bare Knuckle Fighting Championship business was tenuous or overstated, and that Triller could not timely file required periodic financial reports with the SEC, increasing the risk of Nasdaq delisting. The complaint alleges that these disclosure failures led to a suspension of trading in Triller's securities that was not lifted until April 2026, causing investor losses.
October 16, 2024 to December 29, 2025 December 14, 2026
C.D. Cal.
26-cv-11989
Ask about this
Bank of America Corporation NYSE: BAC
The complaint alleges that Bank of America and certain executives misrepresented the scope and severity of deficiencies in its Bank Secrecy Act/anti-money-laundering compliance program, including claims that a 2024 regulatory consent order covered only limited aspects of its compliance programs and that remediation steps had already been substantially completed. The complaint alleges that defendants knew or recklessly disregarded that systemic BSA/AML weaknesses caused the bank to fail to properly monitor large volumes of transactions and to file inaccurate or incomplete suspicious activity reports. The complaint alleges that the truth emerged through regulatory enforcement actions, including penalties announced by FinCEN, the OCC, and OFAC, and that Bank of America shares fell to an intraday low before closing down 4.8 percent on October 14, 2026.
August 1, 2025 to October 13, 2026 December 15, 2026
S.D.N.Y.
1:26-cv-09137
Ask about this
D-Wave Quantum Inc. NASDAQ: QBTS
The complaint alleges that D-Wave and certain of its executives made false and/or misleading statements that materially overstated the company's business, operational, and financial prospects, including in connection with a purported partnership tied to a customer referred to as DarkNX/Accelsius-type disclosures. The complaint alleges the truth began to emerge on August 6, 2026, when D-Wave reported second quarter 2026 revenue of about $3.08 million, missing analyst expectations, causing the stock to fall; the complaint further alleges an additional corrective disclosure on August 25, 2026, when the company announced its CFO's resignation.
February 26, 2026 to August 25, 2026 December 15, 2026
N.D. Cal.
5:26-cv-11953
Ask about this
Skechers U.S.A., Inc. NYSE: SKX
The complaint alleges that Skechers executives and directors, together with 3G Capital Partners and financial adviser Greenhill & Co., misrepresented the fairness of the $63-per-share take-private acquisition by repeatedly lowering the company's internal financial projections after 3G Capital had already locked in its offer price and by privately assuring 3G Capital that tariffs would have minimal impact on future growth while that assessment was not disclosed to public shareholders. The complaint alleges that these alleged omissions caused shareholders who sold their Class A stock between April 24, 2025 and September 12, 2025, including in the take-private transaction, to receive artificially deflated consideration for their shares. The case was first filed on October 21, 2026 in the United States District Court for the Central District of California.
April 24, 2025 to September 12, 2025 December 21, 2026
C.D. Cal.
2:26-cv-12327
Ask about this
Everest Group, Ltd. NYSE: EG
The complaint alleges that Everest and certain of its executives misrepresented that the company had strengthened its underwriting, adequately priced its policies, reduced exposure to casualty risks subject to social inflation, and maintained sufficient reserves, when in fact Everest remained heavily exposed to escalating U.S. casualty claim costs and had insufficient reserves. The complaint alleges the truth began emerging on October 30, 2024 and January 27, 2025 when Everest disclosed billions in reserve strengthening tied to U.S. casualty losses, and alleges a further corrective disclosure on October 27, 2025 when Everest disclosed approximately $478 million in unfavorable prior-year reserve development, after which the stock fell about 11.4% to close at $304.91 per share on October 28, 2025.
February 8, 2024 to October 27, 2025 December 28, 2026
S.D.N.Y.
1:26-cv-09448
Ask about this
O-I Glass, Inc. NYSE: OI
The complaint alleges that O-I Glass and certain executives made materially false and misleading statements about the progress of the company's 'Fit to Win' cost-savings program, concealing delays in achieving targeted cost savings, higher than expected expenses, and operational disruptions that offset the program's benefits. The complaint alleges the truth emerged on July 28, 2026 when the company announced second quarter results that substantially reduced its 2026 adjusted EBITDA and free cash flow guidance and realigned its 2027 Investor Day targets, after which the stock price fell from a closing price of $9.06 to $7.70 per share, a decline of about 15%.
March 14, 2025 to July 28, 2026 December 28, 2026
N.D. Ohio
3:26-cv-02849
Ask about this
Tenax Therapeutics, Inc. NASDAQ: TENX
The complaint alleges that Tenax and certain executives made false and misleading statements overstating the likelihood that its lead drug candidate TNX-103 (oral levosimendan) would succeed in the Phase 3 LEVEL trial for pulmonary hypertension with heart failure with preserved ejection fraction, and that the company's 'derisked' development narrative lacked adequate basis. The complaint alleges the truth emerged on August 10, 2026 when Tenax announced that the LEVEL trial failed to meet its primary endpoint (six-minute walk distance) and key secondary endpoint versus placebo, after which the stock price fell roughly 84 percent.
November 13, 2023 to August 7, 2026 December 28, 2026
M.D.N.C.
1:26-cv-01264
Ask about this
UP Fintech Holding Limited NASDAQ: TIGR
The complaint alleges that UP Fintech materially understated its legal and regulatory risk given continued operations in mainland China, making the company's statements about its business, operations, and prospects materially false and misleading. The complaint alleges the relevant disclosure came on May 22, 2026, when UP Fintech disclosed that its Tiger Brokers subsidiary was under investigation by the China Securities Regulatory Commission for unlicensed cross-border securities business, an investigation that also implicated industry peers, exposing the company to potential administrative penalties and confiscation of alleged illegal income.
April 22, 2024 to June 2, 2026 December 28, 2026
D.N.J.
2:26-cv-13939
Ask about this
Yiren Digital Ltd. NYSE: YRD
The complaint alleges that Yiren Digital Ltd. and certain of its officers made materially false and/or misleading statements and failed to disclose material adverse facts about the company's business, operations, and prospects during the class period. The complaint alleges that on the corrective disclosure date, Yiren's stock fell sharply, including a reported drop of over 44% on October 13, 2026, as the alleged truth was revealed to the market. The case was filed in the U.S. District Court for the Central District of California with a lead plaintiff deadline of December 28, 2026.
April 29, 2026 to October 13, 2026 December 28, 2026
C.D. Cal.
2:26-cv-12673
Ask about this
lululemon athletica inc. NASDAQ: LULU
The complaint alleges that lululemon and certain executives failed to disclose that store traffic and product demand were significantly deteriorating due to negative media and social media commentary and underwhelming new product launches, and that this rendered the company's previously issued FY2026 financial guidance unrealistic. The complaint alleges that on September 3, 2026, lululemon announced weaker than expected second-quarter fiscal 2026 results and sharply cut its FY2026 revenue and EPS guidance, which caused the stock price to fall materially the next trading day.
March 18, 2026 to September 3, 2026 January 4, 2027
D.N.J.
26-cv-14271
Ask about this
Kinross Gold Corporation NYSE: KGC
The complaint alleges that Kinross and certain officers made materially false and misleading statements about the company's production guidance, representing that it could achieve approximately 2 million gold equivalent ounces of production while allegedly concealing that the company lacked the necessary resources to meet that target. The complaint alleges the truth emerged on September 23, 2026, when Kinross issued an operational update reducing its full-year 2026 and 2027 production guidance to approximately 1.84 to 1.86 million gold equivalent ounces, after which the stock price fell from $27.62 to $24.42 per share, a decline of about 11.5%.
February 18, 2026 to September 23, 2026 January 5, 2027
D. Colo.
1:26-cv-05910
Ask about this
Arbor Realty Trust, Inc. NYSE: ABR
The complaint alleges that Arbor Realty and certain officers made materially false and misleading statements about the containment of the company's nonperforming and subperforming loans, including claims that such loans were 'ring-fenced' and that the company had clear visibility to resolving nearly all delinquencies by year-end 2026. The complaint alleges that on October 30, 2026, Arbor Realty disclosed third-quarter 2026 results showing a GAAP net loss of $85.4 million, an increase in nonperforming loans from 19 to 32, and the suspension of its quarterly common stock dividend, after which the stock price fell about 29% to close at $2.14 per share.
February 27, 2026 to October 30, 2026 January 8, 2027
E.D.N.Y.
1:26-cv-07231
Ask about this
CVRx, Inc. NASDAQ: CVRX
The complaint alleges that CVRx and certain current and former officers made materially false and misleading statements about the company's revenue growth, sales practices, regulatory compliance, reimbursement strategy, and sales-force productivity, and that the company engaged in improper marketing of its Barostim device and other sales practices that exposed it to liability under the False Claims Act and Anti-Kickback Statute. The complaint alleges that following disclosure of a Department of Justice civil investigative demand, cuts to revenue guidance, sales-force disruption, and the termination of its Chief Revenue Officer, CVRx's stock price fell about 60%, from $5.94 to $2.39 per share.
July 25, 2023 to August 6, 2026 January 8, 2027
D. Minn.
26-cv-4746
Ask about this
NVIDIA Corporation NASDAQ: NVDA
The complaint alleges that NVIDIA and CEO Jensen Huang made materially false or misleading statements by describing the company's dealings with Megaspeed as routine while failing to disclose Huang's personal relationship with a former Megaspeed executive suspected of ties to Chinese intelligence. The complaint alleges that when this relationship and related risks came to light, NVIDIA shares fell approximately 4.27% to close at $178.67 on November 9, 2026, causing losses to investors who purchased shares during the proposed class period.
October 9, 2025 to November 8, 2026 January 8, 2027
N.D. Cal.
5:26-cv-13448
Ask about this
Lennar Corporation NYSE: LEN
The complaint alleges that Lennar and certain top executives made materially false and misleading statements about the company's land-light operating strategy and the purpose of its spin-off of Millrose Properties, including allegedly concealing that Lennar was capitalizing costs associated with land-bank option agreements to present a more favorable picture of performance. The complaint alleges that on December 16, 2025 Lennar reported disappointing fourth-quarter and full-year 2025 results with adjusted earnings per share far below the prior year and analyst expectations, and that on October 2, 2026 a short-seller report alleged Lennar was using the Millrose spin-off to prop up home sales contrary to its stated purpose, after which Lennar's stock price is alleged to have fallen on both occasions.
February 7, 2025 to October 2, 2026 January 11, 2027
S.D. Fla.
26-cv-28015
Ask about this
NuScale Power Corporation NYSE: SMR
The complaint alleges that NuScale overstated its commercial prospects during the class period, including its purported status as the nuclear small-modular-reactor industry's 'first mover,' its ability to generate revenue from the RoPower Project and work for the Tennessee Valley Authority, and the resulting strength of its remaining cash runway. The complaint alleges that when the truth about these matters was revealed, NuScale's stock price declined, injuring investors who purchased shares during the class period.
February 27, 2026 to September 10, 2026 January 11, 2027
D. Or.
26-cv-02483
Ask about this
Portillo's Inc. NASDAQ: PTLO
The complaint alleges that Portillo's and certain officers failed to disclose that the company had expanded too quickly into markets with insufficient consumer awareness and demand, placed new restaurants too close to existing locations, and cannibalized sales, resulting in dead-site and strategic-reset costs that were not disclosed to investors. The complaint alleges that a series of partial disclosures between August 2025 and May 2026 revealed these issues, and that on the news the stock fell from $5.72 to $4.79 per share (a 16.3% drop) and continued declining to $3.93 per share by May 18, 2026, a cumulative drop of about 31.2%.
September 19, 2023 to May 4, 2026 January 11, 2027
N.D. Ill. Ask about this
Intel Corporation NASDAQ: INTC
The complaint alleges that Intel and executives Lip-Bu Tan and David Zinsner misled investors about the severity of a PC sales slowdown hitting the Client Computing and Physical AI Group, concealed a glut of unsold PC inventory held by partners, and did not disclose that substrate supply constraints were limiting Intel's ability to meet data center chip demand. The complaint alleges that after Intel reported third-quarter 2026 results on October 29, 2026 showing declining segment revenue and fourth-quarter guidance roughly $1.5 billion below analyst estimates, Intel's stock price fell nearly 30% the next trading day.
July 23, 2026 to October 29, 2026 January 12, 2027
N.D. Cal.
5:26-cv-13758
Ask about this
Fervo Energy Company NASDAQ: FRVO
The complaint alleges that Fervo's registration statement and prospectus for its May 2026 IPO failed to disclose that the company's pilot plant was experiencing inconsistent production temperatures and premature thermal decline, that its enhanced geothermal operations were losing injected water at levels above what its commercial plans required, that its drilling costs were not declining as represented, and that it lacked sufficient transmission capacity. The complaint alleges that by the time the action was filed, Fervo's stock had closed as low as $7.79 per share, more than a 71% decline from the $27 per share IPO price.
May 13, 2026 to May 13, 2026 January 18, 2027
S.D. Tex.
4:26-cv-10141
Ask about this
Build-A-Bear Workshop, Inc. NYSE: BBW
The complaint alleges that Build-A-Bear Workshop and certain executives made materially false and misleading statements between May 28, 2026 and August 26, 2026 about its fiscal 2026 financial guidance, which allegedly remained overstated even after an earlier guidance cut, and about the strength of its wholesale relationship with Walmart Inc. The complaint alleges that on August 26, 2026, Build-A-Bear disclosed the termination of its Chief Growth Officer and other negative developments, after which the stock price allegedly fell about 27% in a single day. The complaint alleges that investors who purchased shares during the class period suffered losses as a result of the alleged corrective disclosure.
May 28, 2026 to August 26, 2026 January 19, 2027
E.D. Mo. Ask about this
FMC Corporation NYSE: FMC
The complaint alleges that FMC Corporation and certain officers made materially false and misleading statements about the company's financial outlook and growth projections while failing to disclose that elevated-priced inventory held by distributors was difficult to sell, impairing replenishment orders and threatening the company's ability to generate new sales, revenue, EBITDA and cash flow. The complaint alleges that FMC's statements about its business, operations, and prospects were materially misleading and/or lacked a reasonable basis, and that investors and analysts reacted negatively when the truth was revealed, with the class period running from February 4, 2026 through October 14, 2026.
February 4, 2026 to October 14, 2026 January 19, 2027
E.D. Pa.
2:26-cv-08831
Ask about this
Lead plaintiff deadline passed (75)

Investors who bought during these class periods may still be class members; the passed deadline affects only who can seek appointment as lead plaintiff.

  • ADMA Biologics, Inc. (ADMA), class period August 9, 2024 to March 25, 2026. Reported deadline August 10, 2026.
  • Erasca, Inc. (ERAS), class period January 14, 2025 to April 26, 2026. Reported deadline August 10, 2026.
  • Via Transportation, Inc. (VIA). Reported deadline August 10, 2026.
  • Zillow Group, Inc. (Z), class period February 11, 2025 to May 7, 2026. Reported deadline August 10, 2026.
  • Microsoft Corporation (MSFT), class period May 1, 2025 to January 28, 2026. Reported deadline August 11, 2026.
  • Nano-X Imaging Ltd. (NNOX), class period March 31, 2025 to April 17, 2026. Reported deadline August 11, 2026.
  • Black Rock Coffee Bar, Inc. (BRCB), class period September 12, 2025 to May 12, 2026. Reported deadline August 17, 2026.
  • Embecta Corp. (EMBC). Reported deadline August 17, 2026.
  • First Solar Inc. (FSLR), class period February 26, 2025 to February 24, 2026. Reported deadline August 24, 2026.
  • Peabody Energy Corporation (BTU), class period October 14, 2024 to May 4, 2026. Reported deadline August 24, 2026.
  • ZoomInfo Technologies Inc. (GTM), class period November 3, 2025 to May 11, 2026. Reported deadline August 24, 2026.
  • Futu Holdings Ltd. (FUTU), class period May 24, 2023 to May 27, 2026. Reported deadline August 25, 2026.
  • Genius Group Limited (GNS), class period April 12, 2022 to May 30, 2025. Reported deadline August 28, 2026.
  • Hub Group, Inc. (HUBG), class period April 28, 2023 to May 11, 2026. Reported deadline August 28, 2026.
  • Insulet Corporation (PODD), class period February 21, 2025 to May 26, 2026. Reported deadline August 31, 2026.
  • Photronics, Inc. (PLAB), class period December 10, 2025 to May 27, 2026. Reported deadline September 4, 2026.
  • Intuit Inc. (INTU), class period August 22, 2025 to May 20, 2026. Reported deadline September 8, 2026.
  • Megan Holdings Limited (MGN), class period September 26, 2025 to March 25, 2026. Reported deadline September 8, 2026.
  • GPGI, Inc. (GPGI), class period November 3, 2025 to May 6, 2026. Reported deadline September 14, 2026.
  • Planet Fitness, Inc. (PLNT), class period November 6, 2025 to May 6, 2026. Reported deadline September 14, 2026.
  • Regeneron Pharmaceuticals, Inc. (REGN), class period August 1, 2025 to May 15, 2026. Reported deadline September 14, 2026.
  • Cogent Communications Holdings, Inc. (CCOI), class period February 29, 2024 to May 1, 2026. Reported deadline September 21, 2026.
  • EquipmentShare.com Inc. (EQPT), class period January 23, 2026 to June 23, 2026. Reported deadline September 21, 2026.
  • Microvast Holdings, Inc. (MVST), class period April 1, 2025 to March 16, 2026. Reported deadline September 21, 2026.
  • Park Ha Biological Technology Co., Ltd. (BYAH), class period December 27, 2024 to July 8, 2025. Reported deadline September 21, 2026.
  • Primoris Services Corporation (PRIM), class period August 5, 2025 to June 22, 2026. Reported deadline September 21, 2026.
  • Hertz Global Holdings, Inc. (HTZ), class period May 7, 2026 to June 23, 2026. Reported deadline September 22, 2026.
  • PROCEPT BioRobotics Corporation (PRCT), class period February 28, 2024 to February 25, 2026. Reported deadline September 22, 2026.
  • Wix.com Ltd. (WIX), class period February 19, 2025 to May 12, 2026. Reported deadline September 22, 2026.
  • Bloom Energy Corporation (BE), class period February 27, 2025 to July 8, 2026. Reported deadline September 28, 2026.
  • Capricor Therapeutics, Inc. (CAPR), class period December 17, 2025 to July 26, 2026. Reported deadline September 28, 2026.
  • Rackspace Technology, Inc. (RXT), class period May 7, 2026 to July 8, 2026. Reported deadline September 28, 2026.
  • TruGolf Holdings, Inc. (TRUG), class period September 10, 2025 to May 20, 2026. Reported deadline September 28, 2026.
  • Avis Budget Group, Inc. (CAR), class period February 20, 2025 to April 21, 2026. Reported deadline September 29, 2026.
  • iTonic Holdings Ltd (ITOC), class period September 5, 2024 to July 29, 2025. Reported deadline September 29, 2026.
  • Wise Group plc (WSE), class period May 11, 2026 to July 23, 2026. Reported deadline September 29, 2026.
  • DNOW Inc. (DNOW). Reported deadline October 2, 2026.
  • Pentair plc (PNR), class period April 28, 2026 to July 14, 2026. Reported deadline October 2, 2026.
  • Alarum Technologies Ltd. (ALAR), class period March 20, 2025 to July 2, 2026. Reported deadline October 5, 2026.
  • Alibaba Group Holding Limited (BABA), class period June 26, 2025 to June 24, 2026. Reported deadline October 5, 2026.
  • ARS Pharmaceuticals, Inc. (SPRY), class period March 9, 2026 to June 24, 2026. Reported deadline October 5, 2026.
  • Blaize Holdings, Inc. (BZAI), class period July 18, 2025 to April 28, 2026. Reported deadline October 5, 2026.
  • Datavault AI Inc. (DVLT), class period September 4, 2024 to October 30, 2025. Reported deadline October 5, 2026.
  • Replimune Group, Inc. (REPL), class period October 20, 2025 to April 10, 2026. Reported deadline October 5, 2026.
  • Smartsheet, Inc. (SMAR), class period June 1, 2024 to September 23, 2024. Reported deadline October 5, 2026.
  • Aardvark Therapeutics, Inc. (AARD), class period February 13, 2025 to May 14, 2026. Reported deadline October 13, 2026.
  • HDFC Bank Limited (HDB), class period July 17, 2023 to May 26, 2026. Reported deadline October 13, 2026.
  • The Simply Good Foods Company (SMPL), class period October 24, 2024 to April 8, 2026. Reported deadline October 13, 2026.
  • UWM Holdings Corporation (UWMC), class period March 9, 2026 to August 5, 2026. Reported deadline October 13, 2026.
  • AEVEX Corp. (AVEX), class period April 17, 2026 to June 4, 2026. Reported deadline October 20, 2026.
  • Fractyl Health, Inc. (GUTS), class period January 13, 2025 to January 29, 2026. Reported deadline October 20, 2026.
  • GoDaddy Inc. (GDDY), class period September 3, 2025 to February 24, 2026. Reported deadline October 20, 2026.
  • Taboola.com Ltd. (TBLA), class period May 6, 2026 to August 4, 2026. Reported deadline October 20, 2026.
  • Flotek Industries, Inc. (FTK), class period August 3, 2026 to August 17, 2026. Reported deadline October 26, 2026.
  • York Space Systems Inc. (YSS), class period January 29, 2026 to May 11, 2026. Reported deadline October 26, 2026.
  • Hyliion Holdings Corp. (HYLN), class period May 12, 2026 to June 23, 2026. Reported deadline October 27, 2026.
  • Innventure, Inc. (INV), class period November 17, 2025 to August 13, 2026. Reported deadline October 27, 2026.
  • XTI Aerospace, Inc. (XTIA), class period April 15, 2026 to August 17, 2026. Reported deadline October 27, 2026.
  • Hims & Hers Health, Inc. (HIMS), class period August 4, 2025 to July 29, 2026. Reported deadline November 1, 2026.
  • Papa John's International, Inc. (PZZA), class period August 7, 2025 to August 5, 2026. Reported deadline November 2, 2026.
  • Unicycive Therapeutics, Inc. (UNCY), class period December 29, 2025 to June 29, 2026. Reported deadline November 2, 2026.
  • Beta Bionics, Inc. (BBNX), class period July 30, 2025 to February 24, 2026. Reported deadline November 3, 2026.
  • Celsius Holdings, Inc. (CELH), class period February 21, 2025 to June 3, 2026. Reported deadline November 3, 2026.
  • DICK'S Sporting Goods, Inc. (DKS), class period September 8, 2025 to August 24, 2026. Reported deadline November 3, 2026.
  • The ODP Corporation (ODP). Reported deadline November 3, 2026.
  • Ryde Group Ltd. (RYDE), class period March 6, 2024 to September 11, 2024. Reported deadline November 9, 2026.
  • Dun & Bradstreet Holdings, Inc. (DNB), class period May 13, 2025 to August 26, 2025. Reported deadline November 10, 2026.
  • FuelCell Energy, Inc. (FCEL), class period June 24, 2026 to September 1, 2026. Reported deadline November 10, 2026.
  • Lincoln Educational Services Corporation (LINC), class period May 11, 2026 to August 9, 2026. Reported deadline November 10, 2026.
  • AST SpaceMobile, Inc. (ASTS), class period March 4, 2025 to July 15, 2026. Reported deadline November 13, 2026.
  • Baidu, Inc. (BIDU), class period November 18, 2025 to August 17, 2026. Reported deadline November 13, 2026.
  • AppLovin Corporation (APP), class period February 12, 2026 to August 5, 2026. Reported deadline November 16, 2026.
  • Ardelyx, Inc. (ARDX), class period January 13, 2025 to August 6, 2026. Reported deadline November 16, 2026.
  • Doximity, Inc. (DOCS), class period August 8, 2024 to May 13, 2026. Reported deadline November 16, 2026.
  • Better Home & Finance Holding Company (BETR), class period March 13, 2026 to May 7, 2026. Reported deadline November 20, 2026.

Mass torts

Open to new filings

Depo-Provera (meningioma)

MDL 3140 · U.S. District Court for the Northern District of Florida

Pfizer's master settlement agreement (signed July 21, 2026) and CMO 14's Nov. 30, 2026 settlement-registration deadline remain in place, and the Sept. 18, 2026 Rule 702/general-causation hearing still awaits a ruling. On November 9, 2026, Judge Rodgers approved the creation of two qualified settlement funds in the MDL, one to receive and distribute Pfizer's settlement payments to eligible plaintiffs and a second to handle common-benefit attorneys' fees and litigation expenses, building on the Sept. 9 appointment of an Allocation Master and QSF administrator.

Depo-Provera remains approved by the U.S. Food and Drug Administration.

Ask about this
Open to new filings

GLP-1 drugs: Ozempic, Wegovy, Mounjaro and others (gastroparesis and GI injuries)

MDL 3094 · U.S. District Court for the Eastern District of Pennsylvania

No ruling has been reported from the September Rule 702 evidentiary hearing on cross-cutting causation issues, and no bellwether trial date has been set. A court order entered November 11-12, 2026 canceled the previously scheduled November 17 status conference and instead set a December 3, 2026 hearing on Novo Nordisk's summary-judgment motion and Eli Lilly's gallbladder and general-causation motions, while the December 15 status conference remains on the calendar. A November 2026 case-tracking update citing the JPML's report shows pending actions in MDL 3094 have risen to about 4,082, up from the 4,025 reported a month earlier, while the companion NAION docket, MDL 3163, remains at 278 pending actions.

Ozempic, Wegovy, Rybelsus, Trulicity and Mounjaro remain approved by the U.S. Food and Drug Administration.

Ask about this
Open to new filings

GLP-1 drugs (NAION vision loss)

MDL 3163 · U.S. District Court for the Eastern District of Pennsylvania

CMO 12's front-loaded discovery on general causation and preemption continues, with motions still expected to be fully briefed in 2027. The JPML's Nov. 2, 2026 report shows pending actions in MDL 3163 have grown to 278, up from 247 reported a month earlier.

Ozempic, Wegovy, Saxenda and Trulicity remain approved by the U.S. Food and Drug Administration.

Ask about this
Open to new filings

Chemical hair relaxers and straighteners (uterine and other cancers)

MDL 3060 · U.S. District Court for the Northern District of Illinois

Judge Rowland's October 22 and November 12, 2026 rulings narrowing the general-causation Daubert disputes, CMO 24's extended discovery schedule, and the planned five-case federal bellwether pool with a first federal trial expected in January 2027 remain in place, with pending MDL actions at roughly 12,743 as of the JPML's November 2, 2026 report. Separately, on November 16, 2026, four women settled their claims against L'Oreal's U.S. subsidiary and other hair-relaxer makers on confidential terms during the first trial over hair-relaxer cancer allegations, a state-court case in Cook County, Illinois that began with jury selection on November 9, 2026. The Cook County settlement does not resolve the MDL and no global settlement has been announced in MDL 3060.

Ask about this
Open to new filings

AFFF firefighting foam / PFAS exposure (cancers and other diseases)

MDL 2873 · U.S. District Court for the District of South Carolina

The prioritization of kidney, testicular, thyroid and liver cancer and thyroid disease and ulcerative colitis claims under CMO 35, and the Rule 702 briefing schedule on thyroid- and liver-cancer experts running into early 2027, remain unchanged for non-settling defendants. On November 3, 2026, 3M signed a master settlement agreement to pay up to $7.35 billion (about $5.8 billion in present value, payable 2026 to 2034) to resolve personal-injury AFFF claims against it, reportedly covering roughly 115,000 to 120,000 plaintiffs, and the court entered CMO 39 and CMO 40 on November 4, 2026, setting November 13, 2026 as the deadline to identify eligible claimants to the court. The JPML's Nov. 2, 2026 report lists 15,270 actions pending in MDL 2873, essentially flat from the 15,264 reported a month earlier.

Ask about this
Open to new filings

Bard implanted port catheters (PowerPort)

MDL 3081 · U.S. District Court for the District of Arizona

The Lattanzio bellwether, an infection claim, concluded on Oct. 30, 2026 with a defense verdict for Bard, making the bellwether scorecard two defense verdicts (Cook and Lattanzio) and one plaintiff verdict (the $40 million Divelbliss fracture case), with Bard's Oct. 8 motion for a new trial in Divelbliss still pending. The court has confirmed the fourth bellwether, Hicks, for trial Dec. 1-21, and the JPML's Nov. 2, 2026 report put pending actions in MDL 3081 at 4,345, up from 4,140 reported a month earlier. On November 6, 2026 the parties submitted a joint proposal, reported Nov. 11, to close the MDL to new direct filings on February 28, 2027 and move pending cases to an inactive docket while attorneys negotiate settlements through September 1, 2027; Judge Campbell has not yet ruled on the proposal and no comprehensive settlement has been announced.

Bard implanted port products remain cleared by the U.S. Food and Drug Administration for sale. Certain product lots have been recalled; the FDA recall database lists specific products.

Ask about this
Open to new filings

AngioDynamics implanted port catheters

MDL 3125 · U.S. District Court for the Southern District of California

A bellwether protocol covers infection, fracture and thrombosis cases, with expert discovery in 2027 and Rule 702 motions due Sept. 30, 2027; first trials are not expected before mid-2028. About 430 actions pending.

AngioDynamics implanted port products remain cleared by the U.S. Food and Drug Administration for sale. Certain product lots have been recalled; the FDA recall database lists specific products.

Ask about this
Open to new filings

Covidien (Medtronic) hernia mesh

MDL 3029 · U.S. District Court for the District of Massachusetts

After the $88 million plaintiff verdict in the first bellwether in August 2026, the verdict remains in post-trial motions and the next Covidien trial is still scheduled for Jan. 11, 2027. A November 2026 litigation-tracking update puts the MDL 3029 pending case count at approximately 2,486, up slightly from the roughly 2,453 pending as of Sept. 1, 2026, with no global settlement reached.

Certain Covidien hernia mesh products have been recalled, including a 2023 recall of a Parietex composite mesh product; other Covidien mesh products remain cleared by the U.S. Food and Drug Administration for sale.

Ask about this
Open to new filings

Paragard copper IUD (breakage on removal)

MDL 2974 · U.S. District Court for the Northern District of Georgia

Outcomes of the January, March and May 2026 bellwether trials remain unconfirmed in court sources reviewed, and the February 2025 ruling holding that the injury accrues at removal under certain states' limitation and repose statutes is unchanged. The JPML's Nov. 2, 2026 report lists 4,104 actions pending in MDL 2974, down from the roughly 4,190 previously reported.

Paragard remains approved by the U.S. Food and Drug Administration.

Ask about this
Open to new filings

Suboxone film (dental injuries)

MDL 3092 · U.S. District Court for the Northern District of Ohio

Core discovery, the January 2027 trial-pool selection, and the March 2028 first trial setting remain unchanged. The JPML's November 2, 2026 report shows pending actions in MDL 3092 easing slightly to 2,016, down from the 2,022 reported in October, reversing the prior month's sharp increase.

Suboxone sublingual film remains approved by the U.S. Food and Drug Administration.

Ask about this
Open to new filings

Dupixent (cutaneous T-cell lymphoma)

MDL 3180 · U.S. District Court for the District of New Jersey

Centralized in the District of New Jersey before Judge Zahid N. Quraishi, the litigation moved past its early organizational stage on November 16, 2026, when the court entered pretrial orders allowing new cases to be filed directly into the MDL and setting deadlines for discovery and other pretrial proceedings, consistent with the previously proposed end of the stay on general-causation discovery around that date. The JPML's Nov. 2, 2026 report lists 40 actions pending in MDL 3180, up from roughly 35 previously reported.

Dupixent remains approved by the U.S. Food and Drug Administration.

Ask about this
Open to new filings

3M Bair Hugger forced-air warming (surgical infections)

MDL 2666 · U.S. District Court for the District of Minnesota

Reports of a 2026 bellwether and appeal remain unverified in court sources, and the docket continues to see new filings. The JPML's Nov. 2, 2026 report lists 8,414 actions pending in MDL 2666, essentially unchanged from the 8,424 reported in October.

The 3M Bair Hugger warming system remains cleared by the U.S. Food and Drug Administration for sale; certain accessories were recalled in the past.

Ask about this
Open to new filings

Cartiva synthetic cartilage implant (big toe)

MDL 3172 · U.S. District Court for the Eastern District of Arkansas

Centralized in February 2026 in the Eastern District of Arkansas; proceedings were stayed pending organization, with an organizational meeting held Aug. 26, 2026. About 21 actions pending.

Cartiva, Inc. initiated a recall of the Cartiva Synthetic Cartilage Implant on Oct. 31, 2024 (FDA recall event 95661), citing a higher than expected rate of revision, removal and other hazards.

Ask about this
Handled by a person

Social media adolescent addiction

MDL 3047 · U.S. District Court for the Northern District of California

The Nov. 2, 2026 Snap settlement resolving S.J. and K.D.B.'s claims, Meta's earlier settlement with K.D.B., Florida's Oct. 7 enforcement motion, the $25 billion New Mexico judgment against Meta, and Meta's other scheduled bellwether trials remain as previously reported. On November 13, 2026, personal-injury and school-district plaintiffs in MDL 3047 moved to sanction Meta, alleging it improperly designated thousands of documents as privileged and that a court-ordered re-review has reversed Meta's privilege calls on about 93% of the documents examined so far; Meta called the motion a litigation tactic and filed notice of the special master's report on November 17. The court has set a December 14, 2026 status hearing to address the sanctions dispute, with Meta's response due in December and the next federal bellwether trial still set for February 2027.

Ask about this
Handled by a person

Preterm infant formula (necrotizing enterocolitis, NEC)

MDL 3026 · U.S. District Court for the Northern District of Illinois

Abbott's agreement to settle roughly 2,000 claims and Mead Johnson's Aug. 31 bellwether win remain the key developments, with many claims still unresolved in the MDL and in state courts. The JPML's Nov. 2, 2026 report lists 847 actions pending in the federal MDL 3026, essentially flat from the 844 reported in October.

Ask about this
Handled by a person

Rideshare passenger sexual assault (Uber, Lyft)

MDL 3084 (Uber); MDL 3171 (Lyft) · U.S. District Court for the Northern District of California

The status for MDL 3084 remains largely as previously reported, but on November 16, 2026, Judge Charles Breyer told the parties at a hearing that he intends to begin winding down his oversight of the roughly 6,000-case MDL, with plans to remand some cases back to their originating districts for trial, reportedly prioritizing cases involving more serious allegations. The same day, North Carolina's attorney general filed an amicus brief with the Fourth Circuit urging it to uphold the jury verdict against Uber in a North Carolina bellwether case, arguing Uber should be treated as a common carrier. The next scheduled MDL bellwether trial, A.R.2 v. Uber, remains set for January 2027 and no global settlement has been announced.

Ask about this
Handled by a person

Roblox and Discord child sexual exploitation

MDL 3166 · U.S. District Court for the Northern District of California

CMO status otherwise remains as previously reported, but at a November 16, 2026 case management conference in MDL 3166, the parties reported that one of the plaintiffs selected for the arbitration bellwether test group had been voluntarily dismissed, and the remaining party asked to name a replacement test case on an expedited briefing schedule rather than move other deadlines. Roblox's and Discord's reply briefs on the pending motions to compel arbitration remain due November 20, 2026, and the hearing before Chief Judge Richard Seeborg in the Northern District of California remains scheduled for January 13, 2027.

Ask about this
Handled by a person

ByHeart infant formula (infant botulism)

MDL 3178 · U.S. District Court for the Southern District of New York

ByHeart recalled all of its infant formula nationwide on Nov. 11, 2025 after an infant botulism outbreak (FDA and CDC), and the MDL remains at an early stage with about 22 actions pending. On October 19, 2026, the attorney representing many of the affected families publicized a draft FDA citizen petition seeking to add botulism-causing bacteria to the required safety-testing list for powdered infant formula and its dairy ingredients, to be filed on behalf of 23 families, 21 from the ByHeart outbreak and 2 from a separate Nara Organics outbreak, with public comments sought through Oct. 30, 2026. The petition has not yet been formally filed with the FDA and the agency has not acted on it, so this is a proposed regulatory request tied to the litigation rather than a court ruling or confirmed FDA action.

Ask about this
Closed to new claims or materially limited (17)
  • Philips CPAP / BiPAP / ventilator recall (MDL 3014). The personal-injury Master Settlement Agreement was entered May 9, 2024; under the court's same-day Docket Management Order, claimants who did not register by the settlement's Registration Deadline, and anyone filing later, must produce medical records and device-use proof within 60 days and causation expert reports within 90 days or face dismissal with prejudice.
  • 3M Combat Arms earplugs (MDL 2885). 3M's settlement of Combat Arms earplug claims was announced Aug. 29, 2023, with eligible claimants identified as of a Sept. 12, 2023 reference date and awards paid through the settlement administrators; litigants who declined the settlement remain subject to CMO 57's litigation requirements.
  • Zantac / ranitidine (federal MDL 2924). Judge Robin Rosenberg excluded plaintiffs' general-causation experts in December 2022; plaintiffs' Eleventh Circuit appeal was argued Oct. 10, 2025, and its outcome is unverified as of September 2026.
  • Zantac / ranitidine (Delaware state court). In July 2025 the Delaware Supreme Court reversed the Superior Court ruling that had allowed plaintiffs' expert testimony (342 A.3d 1131), returning the cases for expert review under the corrected standard; GSK had separately agreed to settle roughly 80,000 state-court claims.
  • Roundup: failure-to-warn claims (Monsanto Co. v. Durnell). On June 25, 2026, the U.S. Supreme Court held 7-2 that FIFRA expressly preempts a state-law failure-to-warn claim that would require a cancer warning on Roundup's label, reversing and remanding the Missouri judgment.
  • Roundup: proposed nationwide NHL class settlement (King v. Monsanto, Missouri state court). The opt-out deadline for the proposed class settlement of current and future Roundup non-Hodgkin lymphoma claims passed June 4, 2026, and the fairness hearing is set for Sept. 14, 2026; class members diagnosed after March 4, 2026 may apply within six years of diagnosis if the settlement becomes final.
  • Johnson & Johnson talc (ovarian cancer; MDL 2738 and related state cases). On July 22, 2026, the MDL court ordered plaintiffs to show why remaining ovarian-cancer talc claims should not be dismissed for lack of specific-causation proof, and on July 27, 2026, J&J announced a proposed resolution of about 76,000 existing ovarian talc claims, conditioned on 95% participation and excluding mesothelioma claims.
  • Paraquat (MDL 3004). Syngenta and Chevron executed a Master Settlement Agreement with plaintiffs' leadership on Aug. 4, 2025, and CMO 25 (June 12, 2026) imposes Lone Pine-type requirements, including a case-specific causation expert report and a Parkinson's diagnosis by a neurologist or movement-disorder specialist, on non-settling, ineligible and newly filed plaintiffs.
  • Camp Lejeune Justice Act. The Department of the Navy states that the CLJA filing deadline passed on Aug. 10, 2024 and that it is no longer accepting new CLJA claims; claims filed by the deadline remain under review.
  • Acetaminophen / Tylenol autism-ADHD (MDL 3043). Judge Denise Cote granted defendants' motions to exclude plaintiffs' expert opinions on Dec. 18, 2023 and July 10, 2024, and the court's MDL page lists no later orders.
  • Exactech orthopedic implants (MDL 3044). Exactech filed Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware on Oct. 29, 2024; the general claims bar date was Feb. 7, 2025, and the plan was confirmed Sept. 17, 2025 and became effective Oct. 31, 2025.
  • Hernia mesh: Davol/C.R. Bard polypropylene mesh (MDL 2846). CMO 55 (Nov. 21, 2024) appointed special masters and set an Intensive Settlement Process for opt-out and other non-settling claimants beginning on or about Jan. 4, 2027, with cases filed after the Docket Control Orders eligible only if Administering Counsel and Bard agree.
  • Hernia mesh: Ethicon Physiomesh (MDL 2782). The JPML's Sept. 1, 2026 report lists no pending actions in MDL 2782 (4,054 total actions).
  • Taxotere / docetaxel (MDL 2740). The JPML's Sept. 1, 2026 report lists 81 pending of 15,572 total actions in MDL 2740 (hair loss) and 140 pending of 433 in the separate eye-injury MDL 3023.
  • Gardasil (MDL 3036). The Fourth Circuit on Sept. 4, 2025 affirmed dismissal of three bellwether cases on Vaccine Act timeliness grounds, and only 6 of 258 actions remained pending in MDL 3036 as of September 2026.
  • Juul (MDL 2913). The JPML's Sept. 1, 2026 report lists 11 pending of 7,071 total actions in MDL 2913.
  • Baby food heavy metals, autism/ADHD (MDL 3101). On Aug. 13, 2026, Judge Jacqueline Scott Corley indicated she would grant summary judgment against a substantial portion of the MDL's ADHD and autism claims, following her earlier ruling that plaintiffs' causation evidence was unreliable.

Do not see your case? If a company, product, or practice that affected you is not listed, tell the firm anyway. Many matters begin that way. Case evaluation.

Schwartz & Associates, PC is responsible for the content of this website. Responsible attorney: Lou Schwartz, Esq. The firm may refer matters to, or handle them together with, other lawyers.

Do not stop taking a prescribed medication without first consulting with your doctor. Discontinuing a prescribed medication without your doctor's advice can result in injury or death. Consult your physician before making any decision regarding prescribed medication or medical treatment.

Reviewed daily from JPML pending-MDL statistics, MDL court orders and pages, FDA/CDC notices, openFDA recall records and reputable legal press; last reviewed November 21, 2026. Status can change quickly; confirm before relying.

If something happened to more people than you, tell us.

Many class actions begin with one person who noticed a pattern. Reviewing your information costs nothing and creates no obligation.